Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.55 |
| ▸ | CTSL | P07711 | 4/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054417 | 1.00 | SYK (0.56) | SYKCTRB1ATMCTSKCTSL | |
| SCHEMBL12220545 | 0.85 | SYK (0.69) | SYKCTRB1ATMCTSKCTSL | |
| SCHEMBL21333945 | 0.85 | CTSL (0.62) | CTRB1ATMCTSKCTSLCTSS | |
| SCHEMBL20820039 | 0.84 | CASP1 (0.58) | CTRB1ATMCTSLCTSS | |
| SCHEMBL13572927 | 0.84 | ATM (0.59) | SYKCTRB1ATMCTSKCTSL | |
| SCHEMBL14999596 | 0.84 | ATM (0.59) | SYKCTRB1ATMCTSKCTSL | |
| SCHEMBL6407665 | 0.84 | ATM (0.59) | SYKCTRB1ATMCTSKCTSL | |
| SCHEMBL5973119 | 0.84 | CTSL (0.58) | CTSKCTSLCTSS | |
| SCHEMBL2059541 | 0.83 | ATM (0.62) | CTRB1ATMCTSKCTSLCTSS | |
| SCHEMBL14561268 | 0.83 | ATM (0.56) | SYKCTRB1ATMCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696707-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| CN-106414473-B | Polyene macrolide derivatives | 盐野义制药株式会社 | 2020-03-13 | — | — | CN | disclosed |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10246478-B2 | Polyene macrolide derivative | SHIONOGI & CO., LTD. (JP) | 2019-04-02 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| EP-3156410-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9310366-B2 | Anthrax carbohydrates, synthesis and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20130260402-A1 | ANTHRAX CARBOHYDRATES, SYNTHESIS AND USES THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (WASHINGTON D.C.) | 2013-10-03 | — | — | US | disclosed |
| US-8420607-B2 | Anthrax carbohydrates, synthesis and uses thereof | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2044194-B1 | ANTHRAX CARBOHYDRATES, SYNTHESIS AND USES THEREOF | UNIV GEORGIA (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-0850244-A1 | TOXOPLASMA GONDII GLYCOCONJUGATES | Akzo Nobel N.V. (NL) | 1998-07-01 | — | — | EP | disclosed |
| WO-1998014192-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997010249-A1 | TOXOPLASMA GONDII GLYCOCONJUGATES | AKZO NOBEL N.V. (NL) | 1997-03-20 | — | — | WO | disclosed |
| US-5608045-A | DISODIUM SALT BY POT REACTING RHAMNOSE TRIACETATE WITH PHENYL DICHLOROPHOSPHATE IN PRESENCE OF TRIETHYLAMINE AND WITH /S/LEU-/S/TRP-OET IN SOLVENT, SAPONIFYING SEPARATED PRODUCT WITH ETHANOLIC BASE IN COLD, EVAPORATING ETHANOL | ADIR ET COMPAGNIE (FR) | 1997-03-04 | — | — | US | disclosed |
| US-5591728-A | ENZYME INHIBITORS WITH AMIDE AND ESTER GROUPS | ADIR ET COMPAGNIE (FR) | 1997-01-07 | — | — | US | disclosed |
| US-5481030-A | USED AS AN ENDOTHELIN CONVERTASE INHIBITOR | ADIR ET COMPAGNIE (FR) | 1996-01-02 | — | — | US | disclosed |
| EP-0680988-A2 | Carbamate compounds and coating compositions comprising same | CYTEC TECHNOLOGY CORP. (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0639586-A1 | Phosphonic acid derivatives, process for their preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 1995-02-22 | — | — | EP | disclosed |
| EP-0152820-A2 | Carbamate compounds, compositions and method of making the same | CYTEC TECHNOLOGY CORP. (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4484994-A | REACTING EPOXY RESIN WITH AMINES HAVING SECONDARY AMINE AND CARBAMATE GROUPS | AMERICAN CYANAMID COMPANY (US) | 1984-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | SYK 3755/4885CTRB1 636/4885ATM 4287/4885 |
| US-10246478-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | SYK 3755/4885CTRB1 636/4885ATM 4287/4885 |
| US-20190135847-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | SYK 3755/4885CTRB1 636/4885ATM 4287/4885 |
| US-10696707-B2 | Polyene macrolide derivative | ERG28, RPL23, RPL10 | SYK 3755/4885CTRB1 636/4885ATM 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.